Navigation Links
Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer'

NEWPORT NEWS, Va., Feb 7 /PRNewswire/ -- Dilon Technologies, makers of a gamma imaging system optimized for early breast cancer detection, has appointed Robert G. Moussa to the position of President and Chief Executive Officer.

Moussa has a long and successful record in the medical device industry having held a number of senior positions at both Sherwood Medical Industries and Mallinckrodt Medical -- a health care corporation he ran as CEO for a number of years. In his four years at Mallinckrodt, Moussa grew revenues from $350 million to $1.2 billion and increased the operating margins from 18 percent to 22 percent. Additionally, he has successfully launched a number of new products in the diagnostic, nuclear medicine and medical device markets.

Dilon "the standard of care"

Regarding Dilon Moussa commented, "Dilon has advanced technology that will make it a major weapon in the battle against cancer. Based upon existing clinical results, it will become the standard of care as an adjunct diagnostic tool in the diagnosis of breast cancer."

4-Point Strategy

Under Moussa's leadership, Dilon will adopt a 4-point strategy to increase market share.
The strategy includes:

1) Expansion of the established installed base in the US through strategic

use of sales and distribution.

2) Initiating a major international expansion strategy. This is based on

Dilon's international potential of being at least as large as that in

the US.

3) Working with the Medical Establishment, expand the capabilities and

indications for the existing BSGI product.

4) Pursue acquisitions of products, technologies and companies that offer

a strategic fit with Dilon.

Moussa added, "I am confident that by adopting and accelerating these measures, we will achieve the objective of making Dilon the standard of care in the diagnostic field."

About Dilon Technologies LLC

Dilon Technologies LLC is bringing innovative new medical products to the market based on research conducted at leading national research laboratories. Dilon's cornerstone product is the Dilon 6800 Gamma Camera -- a high-resolution, anatomic-specific gamma camera, which is now being used to perform Breast-Specific Gamma Imaging (BSGI), a molecular imaging technique that images the metabolic activity of breast lesions through radiotracer uptake. Several leading medical centers around the country are now offering BSGI to their patients, including: Beth Israel Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Alexian Brothers Medical Center, Chicago; Methodist Hospital, Philadelphia; and West Valley Imaging, Las Vegas.

To find out more about BSGI or the Dilon 6800 Gamma Camera please visit

SOURCE Dilon Technologies LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
4. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
5. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
6. David Mott Appointed Non Executive Director at Shire
7. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
8. John Marshall and Kevin McGuinness Appointed to Ellex Board
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
11. Genelabs Technologies to Present at the BIO CEO & Investor Conference
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
Breaking Biology Technology:
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
Breaking Biology News(10 mins):